Bromotetrandrine

Bromotetrandrine is a potent inhibitor of P-glycoprotein (P-gp) -mediated multidrug resistance (MDR) . Bromotetrandrine shows significant MDR reversal activity in vitro and in vivo, which may be related to the inhibition of P-gp overexpression and the increase in intracellular accumulation of anticancer agents. Bromotetrandrine is a brominated derivative of tetrandrine, which is promising for MDR modulator for tumor assessment[1][2].

Product Specifications

CAS Number

[62067-29-2]

Product Name Alternative

5-Bromotetrandrine; BrTet; W198

UNSPSC

12352005

Target

Drug Derivative; P-glycoprotein

Related Pathways

Membrane Transporter/Ion Channel; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

COC1=C2C3=C(CCN([C@@]3([H])CC4=CC=C(OC)C(OC5=CC=C(C[C@@]6([H])C7=CC(O2)=C(C=C7CCN6C)OC)C=C5)=C4)C)C(Br)=C1OC

Molecular Formula

C38H41BrN2O6

Molecular Weight

701.65

References & Citations

[1]Zheng L, et al. Pharmacokinetics and safety of bromotetrandrine (BrTet, W198) after single-dose intravenous administration in healthy Chinese volunteers. J Clin Pharm Ther. 2010 Feb;35 (1) :113-9.|[2]Jin J, et al. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother Pharmacol. 2005 Feb;55 (2) :179-88.